The article reports that a new type of calcineurin inhibitor showing strong promise in a clinical trial could prove to be one of the safest and most effective therapies for plaque psoriasis. In a study of people aged 18 to 6...
Johnson & Johnson announced on Monday that in a late-stage clinical trial, the company's oral drug for the treatment of specific skin conditions has achieved its primary goal of significantly improving the condition of the skin to a point where it is clear or near clear and reducing the form...
janus kinase (JAK) inhibitors, that show a lot of promise. These inhibitors block specific enzymes (JAK1, JAK2, and JAK3) that signal your cells to make more inflammation. One study found that people who took a JAK inhibitor for just over 3 months were twice as likely to have a strong...
Dr. Isakson: Celebrex is specifically indicated for the treatment of osteoarthritis and rheumatoid arthritis. There currently is no data to support the use of Celebrex for other conditions. Nevertheless, we do have trials, either ongoing or soon to begin, in other potential uses, for example in...
This decision was predicated on the significant improvement in morbidity (measured by SVR12) and the pressing medical necessity for effective hepatitis C treatment at the time. This observation led to the identification of the second independent variable, termed ‘Therapeutic break-through’. Excluding...
The study, of more than 150 adults with Crohn's, found that just two weeks of treatment sent many into remission—meaning they had few to no symptoms of theinflammatory bowel disease28 days after the study began. Experts said the findings are encouraging. For one, the drug is a pill, wh...
Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat a common skin disease as an "incredibly promising" treatment for alcohol use disorder. Their study was recently published in theJournal of Clinical Investigation. ...
Treatment 1. Introduction Bullous pemphigoid (BP) is one of the most prevalent subepidermal primary blistering disorders of the skin. It has a predilection for affecting elderly males, characteristically those over 70 years of age, and presents with blistering eruptions, tense pruritic bullae, and ...
We also use optional cookies for advertising, personalisation of content, usage analysis, and social media. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with...
Four companies—GSK, Biogen, Chiesi and UCB—secured three approvals each in 2023. The trio for UCB included two nods which came on the same day in October, for plaque psoriasis medicineBimzelxand myasthenia gravis treatmentZilbrysq. The Belgium-based company also earned a green...